Skip to main content
SpringerLink
Log in

Non-Candida Fungal Infections in the Intensive Care Unit

North American Perspective

  • Chapter
Fungal Infection in the Intensive Care Unit

Part of the book series: Perspectives on Critical Care Infectious Diseases ((CCID,volume 6))

  • 91 Accesses

Abstract

Infections caused byCandidaspecies are the most common mycotic diseases encountered in the intensive care unit (ICU), accounting for almost 80% of the fungal infections among patients requiring critical care. However, an increasing number of other opportunistic fungal pathogens are encountered in these patients, includingAspergillusspeciesCryptococcus neoformans FusariumspeciesPneumocystis carinii Scedosporiumspecies, and the Zygomycetes. In addition, in many parts of the Americas, endemic fungal pathogens, such asHistoplasma capsulatum Coccidioides immitisandBlastomyces dermatitidisthat cause community-acquired infections, may be encountered among patients in intensive care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nelson PE, Dignani Ai, Anaissie.E. Taxonomy, biology, and clinical aspects ofFusariumspecies. Clin Microbiol Rev 1994;7:479–504.

    PubMed  CAS  Google Scholar 

  2. Boutati El, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years’ experience at a cancer center and implications for management. Blood 1997;90:999–1008.

    Google Scholar 

  3. Krcmery V, Jesenska Z, Spanik S. Fungemia due toFusariumspecies in cancer patients. J Hosp Infect 1997;35:223–8.

    Article  Google Scholar 

  4. Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994;28 (Suppl I):7–15.

    Article  PubMed  Google Scholar 

  5. Garnis AS, Gudnason T, Giebink GS, Ramsay NKC. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis 1991;13:1077–88.

    Article  Google Scholar 

  6. Hennequin C, Laverde V, Poirot JL. Invasive Fusarium infections: a retrospective survey of 31 cases. J Med Vet Mycol 1997;35:107–14.

    Article  PubMed  CAS  Google Scholar 

  7. Wheeler MS, McGinnis MR, Schell WA, Walker DH. Fusarium infection in burned patients. Am J Clin Pathol 1981;75:304–11.

    PubMed  CAS  Google Scholar 

  8. Guarro J, Gene J. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis 1995;14:741–54.

    Article  PubMed  CAS  Google Scholar 

  9. Ammari LK, Puck JM, McGowan KL. Catheter-relatedFusarium solanifungemia and pulmonary infection in a patient with leukemia in remission. Clin Infect Dis 1993;16:148–50.

    Article  PubMed  CAS  Google Scholar 

  10. Girmenia C, Gastaldi R, Martino P. Catheter-related cutaneous aspergillosis complicated by fungemia and fatal pulmonary infection in an HIV-positive patient with acute lymphocytic leukemia. Eur J Clin Microbiol Infect Dis 1995;14:524–6.

    Article  PubMed  CAS  Google Scholar 

  11. Merz WG, Karp JE, Hoagland M, et al. Diagnosis and successful treatment of fusariosis in the compromised host.JInfect Dis 1988;158:1046–54.

    Article  CAS  Google Scholar 

  12. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B againstAspergillusandFusariumspp. Antimicrob Agents Chemother 2002;46:245–7.

    Article  PubMed  CAS  Google Scholar 

  13. Raad I, Hachem R. Treatment of central venous catheter-related fumgemia due toFusarium oxysporum.Clin Infect Dis 1995;20:709–11.

    Article  PubMed  CAS  Google Scholar 

  14. Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenicFusariumspecies colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001;33:1871–8.

    Article  PubMed  CAS  Google Scholar 

  15. Eckburg PB, Zolopa AR, Montoya JG. Invasive fungal sinusitis due toScedosporium apiospermumin a patient with AIDS. Clin Infect Dis 1999;29:212–3.

    Article  PubMed  CAS  Google Scholar 

  16. Kim HU, Kim SC, Lee HS. Localized skin infection due toScedosporium apiospermum:report of two cases. Br J Dermatol 1999;141:605–6.

    Article  PubMed  CAS  Google Scholar 

  17. Bernstein EF, Schuster MG, Stieritz DD, Heuman PC, Uitto J. Disseminated cutaneousPseudallescheria boydii.Br J Dermatol 1995;132:456–60.

    Article  PubMed  CAS  Google Scholar 

  18. Ksiazek SM, Morris DA, Mandelbaum S, Rosenbaum PS. Fungal panophthalmitis secondary toScedosporium apiospermum (Pseudallescheria boydii)keratitis. Am J Ophthalmol 1994;1 18:531–3.

    Google Scholar 

  19. McKelvie PA, Wong EY, Chow LP, Hall AJ. Scedosporium endophthalmitis: two fatal cases of Scedosporium infection presenting with endophthalmitis. Clin Exp Opththalmol 2001;29:330–4.

    Article  CAS  Google Scholar 

  20. Walsh TJ, Peter J, McGough DA, et al. Activities of amphotericin B and antifungal azoles alone and in combination againstPseudallescheria boydii.Antimicrob Agents Chemother 1995;39:1361–4.

    Article  PubMed  CAS  Google Scholar 

  21. Galgiani JN, Stevens DA, Graybill JR, et al.Pseudallescheria boydiiinfections treated with ketoconazole. Chest 1986;86:219–24.

    Article  Google Scholar 

  22. Goldberg SL, Geha DJ, Marshall WF, Inwards DJ, Hoagland HC. Successful treatment of simultaneous pulmonaryPseudallescheria boydiiandAspergillus terreusinfection with oral itraconazole. Clin Infect Dis 1993;16:803–5.

    Article  PubMed  CAS  Google Scholar 

  23. Nesky MA, McDougal EC, Peacock JE.Pseudallescheria boydiibrain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000;31:673–7.

    Article  PubMed  CAS  Google Scholar 

  24. .Scedosporium prolificansStudy Group. Deep infections caused byScedosporium prolificans.A report on 16 cases in Spain and a review of the literature. Medicine (Baltimore) 1997;76:256–65.

    Google Scholar 

  25. Wilson CM, O’Rourke EJ, McGinnis MR, Salkin IF.Scedosporium inflatum:clinical spectrum of a newly recognized pathogen. J Infect Dis 1990;161:102–7.

    Article  CAS  Google Scholar 

  26. Lopez L, Gasztelurritia L, Cuenca-Estrella M, et al.Infection and colonization byScedosporium prolificans.Enfermedades Infecciosas y Microbiologia Clinica 2001;19:308–13.

    PubMed  CAS  Google Scholar 

  27. Tapia M, Richard C, Baro J, et al.Scedosporium inflatuminfection in immunocompromised haematological patients. Br J Haematol 1994;87:212–4.

    Article  PubMed  CAS  Google Scholar 

  28. Wood GM, McCormack JG, Muir DB, et al. Clinical features of human infection withScedosporium inflatum.Clin Infect Dis 1992;14:1027–33.

    Article  PubMed  CAS  Google Scholar 

  29. Espinel-Ingroff A. Comparison of the in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950–6.

    PubMed  CAS  Google Scholar 

  30. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236–301.

    Article  PubMed  CAS  Google Scholar 

  31. Scholer Hi, Muller E, Schipper AA. Mucorales. In: Fungi Pathogenic for Humans and Animals. Howard DH, ed. New York: Marcel Dekker; 1983:9–59.

    Google Scholar 

  32. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984;74:150–60.

    Article  PubMed  CAS  Google Scholar 

  33. Reinhardt D, Kaplan W, Ajello L. Experimental zygomycosis in alloxan-diabetic rabbits. Infect Immun 1970;2:404–13.

    PubMed  CAS  Google Scholar 

  34. Tedder M, Spratt JA, Anstadt MP, et al.Pulmonary mucormycosis. Ann Thorac Surg. 1994;57:1044–50.

    Article  PubMed  CAS  Google Scholar 

  35. Boelaert JR, van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxyopyridine chelators have no effect. Kidney Int 1994;45:667–71.

    Article  PubMed  CAS  Google Scholar 

  36. van Cutsem J, Boelaert JR. Effects of deferoxamine, ferrioxamine, and iron in experimental mucormycosis (zygomycosis). Kidney Int 1989;36:1061–8.

    Article  PubMed  Google Scholar 

  37. Meyers BR, Wormser GP, Hurst SF, Blitzer A. Rhinocerebral mucormycosis: premortem diagnosis and therapy. Arch Intern Med 1979;139:557–60.

    Article  PubMed  CAS  Google Scholar 

  38. Pillsbury HC, Fischer ND. Rhinocerebral mucormycosis. Arch Otolaryngol 2000;103:600–4.

    Google Scholar 

  39. Blitzer A, Lawson W, Meyers BR, Biller HF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope 1980;90:635–48.

    Article  PubMed  CAS  Google Scholar 

  40. Sohail MA, Al Khabori M, Hyder J, Verma A. Acute fulminant fungal sinusitis: clinical presentation, radiological findings and treatment. Acta Tropica 2001;80:177–85.

    Article  PubMed  CAS  Google Scholar 

  41. Straatsma BR, Zimmerman LE, Gass JDM. Phycomycosis: a clinical pathologic study of fifty-one cases. Lab Invest 1962;11:963–85.

    PubMed  CAS  Google Scholar 

  42. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KVI. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000;30:851–6.

    Article  PubMed  CAS  Google Scholar 

  43. Rinaldi MG. Zygomycosis. Infect Dis Clin North Am 1989;3:19–42.

    PubMed  CAS  Google Scholar 

  44. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989;8:323–30.

    Article  PubMed  CAS  Google Scholar 

  45. Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J. Adjuvant hyperbaric oxygen treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988;10:551–9.

    Article  PubMed  CAS  Google Scholar 

  46. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383–96.

    Article  PubMed  CAS  Google Scholar 

  47. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony stimulating factor. Clin Infect Dis 1997;24:192–6.

    Article  PubMed  CAS  Google Scholar 

  48. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001;20:460–6.

    PubMed  CAS  Google Scholar 

  49. Terrell CL. Antifungal agents II. The azoles. Mayo Clin Proc 1999;74:78–100.

    Article  CAS  Google Scholar 

  50. Dannaoui E, Meis JFG, Mouton JW, Verweij PE. Evaluation of combinations of antifungal agents against zygomycetes. In: Abstracts of the 40thInterscience Conference on Antimicrobial Agents and Chemotherapy, 2000;abstract 934,p.368.

    Google Scholar 

  51. Dannaoui E, Meletiadis J, Meis J, Mouton JW, Verweij PE. In vitro activity of conventional and new antifungals against zygomycetes. In: Abstracts of the 40thInterscience Conference on Antimicrobial Agents and Chemotherapy, 2000;abstract 939, p.370.

    Google Scholar 

  52. Fisher DJ, Christy C, Spafford P, et al. NeonatalTrichosporon beigeliiinfection: report of a cluster of cases in a neonatal intensive care unit. Pediatr Infect Dis J 1993;12:14955.

    Google Scholar 

  53. Gueho E, Faergemann J, Lyman C, Anaissie EJ. Malassezia and Trichosporon: two emerging pathogenic basidiomycetous yeast-like fungi. J Med Vet Mycol 1994;32, suppl. 1:367–78.

    Article  PubMed  Google Scholar 

  54. Walsh TJ, Pizzo PA. Nosocomial fungal infections. Ann Rev Microbiol 1988;42:517–45.

    Article  CAS  Google Scholar 

  55. Walsh TJ. Trichosporonosis. Infect Dis Clin North Am 1989;3:43–51.

    PubMed  CAS  Google Scholar 

  56. Melcher GP, Rinaldi MG, Lee JW, Pizzo P, Walsh T. Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol 1991;29:192–6.

    PubMed  CAS  Google Scholar 

  57. Lyman CA, Garrett KF, Pizzo PA, Walsh TJ. Response of human polymorphonuclear leukocytes and monocytes toTrichosporon beigelii:Host defense against an emerging opportunistic pathogen. J Infect Dis 1994;170:1557–65.

    Article  CAS  Google Scholar 

  58. Muranaka H, Suga M, Nakagawa K, et al. Effects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis. Infect Immun 1997;65:3422–9.

    PubMed  CAS  Google Scholar 

  59. Hoy J, Hsu KC, Rolston K, Hopfer RL, Bodey GP.Trichosporon beigeliiinfection: a review. Rev Infect Dis 1986;8:959–67.

    Article  PubMed  CAS  Google Scholar 

  60. Walsh TJ, Melcher GP, Rinaldi MG, et al.Trichosporon beigeliian emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990;28:1616–22.

    PubMed  CAS  Google Scholar 

  61. Anaissie EJ, Bodey GP, Kantarjian H, Ro J, Vartivarian SE. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989;11:369–78.

    Article  PubMed  CAS  Google Scholar 

  62. Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) 1986;65:268–79.

    Article  CAS  Google Scholar 

  63. Anaissie EJ, Hachem R, Karyotakis NCet al.Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob Agents Chemother 1994;38:2541–4.

    Article  PubMed  CAS  Google Scholar 

  64. Anaissie EJ, Gokaslan A, Hachem Ret al.Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992;15:781–7.

    Article  PubMed  CAS  Google Scholar 

  65. Bradsher RW. Blastomycosis. Clin Infect Dis 1992;14, Suppl. 1:S82–S90.

    Article  PubMed  Google Scholar 

  66. Wheat Li, Connolly-Springfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990;69:361–74.

    Google Scholar 

  67. Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 1990;69:384–91.

    CAS  Google Scholar 

  68. Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993;6:89–117.

    PubMed  CAS  Google Scholar 

  69. Williams B, Fojtasek M, Connolly-Stringfield P, Wheat J. Diagnosis of histoplasmosis by antigen detection during an outbreak in Indianapolis, Ind. Arch Pathol Lab Med 1994;118:1205–8.

    PubMed  CAS  Google Scholar 

  70. Arsura EL, Bellinghausen PL, Kilgore WB, et al., Septic shock in coccidioidomycosis. Crit Care Med 1998;26:62–5.

    Article  PubMed  CAS  Google Scholar 

  71. Booker KJ. Blastomycosis-induced respiratory failure: the successful application of continuous positive airway pressure. Heart Lung 1996;25:384–7.

    Article  PubMed  CAS  Google Scholar 

  72. Wong-Beringer A, Jacobs R, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603–18.

    Article  PubMed  CAS  Google Scholar 

  73. Wheat J, Hafner R, Korzun AH, etal. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995;98;361–42.

    Article  Google Scholar 

  74. Catanzaro A, Galgiani JN, Levine BE, etal. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidmycosis. Am J Med 1995;98;249–56.

    Article  PubMed  CAS  Google Scholar 

  75. Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA, NIANID Mycises Study Group. Itrcainzole treatment of coccidiodomycosis. Am J Med 1990;89:292–300.

    Google Scholar 

  76. Grabill JR Sobel J, Saag M, etal. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococal meningitis. Clin Infect Dis 2000;30:47–54.

    Article  Google Scholar 

  77. Van der Horst C, Saag M, Cloud G, etal.Treatment of cryptococcal meningitisassociated with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:15–21.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Health Science Center, San Antonio, Texas, USA

    Marcos I. Restrepo & John R. Graybill

Authors
  1. Marcos I. Restrepo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John R. Graybill
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Wales College of Medicine, Cardiff, UK

    R. A. Barnes

  2. Centers for Disease Control and Prevention, Atlanta, Georgia, USA

    D. W. Warnock

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Restrepo, M.I., Graybill, J.R. (2002). Non-Candida Fungal Infections in the Intensive Care Unit. In: Barnes, R.A., Warnock, D.W. (eds) Fungal Infection in the Intensive Care Unit. Perspectives on Critical Care Infectious Diseases, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0977-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0977-6_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5333-1

  • Online ISBN: 978-1-4615-0977-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation